|
New Technologies Special Interest Group
Breakfast Meeting Agenda
| Monday, October 26, 2009 |
7:00 AM–8:30 AM |
|
Breakfast Meeting |
|
|
New Technologies Special Interest Group |
Leaders: Brinda Mahadevan, Schering Plough Research Institute and Patricia A. Escobar, Boehringer-Ingelheim Pharmaceuticals |
|
|
Mini-Symposium: “Genetic Toxicity of Oligonucleotide Therapeutics”
7:00 AM–7:15 AM
Breakfast
Discussion on general activities of the SIG and webpage development
Symposium/workshop topic suggestions for the EMS 2010 annual meeting theme “Complex Systems in Biology and Risk Assessment.”
7:15 AM–7:40 AM
Biochemistry of Triple Helix Formation; Implications for Oligonucleotide Therapeutics
Zhanna Sobol (Pfizer Global R&D)
7:35 AM–8:00 AM
Toxicology Associated with Oligonucleotide Therapeutics
Husam Younis ( Isis Pharmaceuticals Inc.)
8:00AM–8:25 AM
What is an Appropriate Genetic Toxicological Endpoint Regarding Oligonucleotide Therapeutics?
Kevin Sweder (Bristol-Myers Squibb)
8:25 AM–8:30 AM
General Discussion and Concluding Remarks
| 
General Information